BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Assenagon Asset Management S.A. | 116,503 | $40,385,000 | 0.15% |
| VAN STRUM & TOWNE INC. | 1,000 | $347,000 | 0.15% |
| MACQUARIE GROUP LTD | 375,964 | $130,324,000 | 0.15% |
| VOYA INVESTMENT MANAGEMENT LLC | 166,971 | $57,879,000 | 0.15% |
| L. Roy Papp & Associates, LLP | 2,715 | $941,000 | 0.14% |
| Newfound Research LLC | 178 | $62,000 | 0.13% |
| Icon Wealth Partners, LLC | 3,155 | $1,094,000 | 0.13% |
| KORNITZER CAPITAL MANAGEMENT INC /KS | 18,214 | $6,314,000 | 0.13% |
| FORA Capital, LLC | 1,825 | $633,000 | 0.13% |
| CIM INVESTMENT MANAGEMENT INC | 871 | $302,000 | 0.12% |
| SIT INVESTMENT ASSOCIATES INC | 11,675 | $4,047,000 | 0.12% |
| Aull & Monroe Investment Management Corp | 700 | $243,000 | 0.12% |
| B. Metzler seel. Sohn & Co. AG | 20,977 | $7,271,000 | 0.12% |
| State of Wyoming | 546 | $189,000 | 0.12% |
| Pearl River Capital, LLC | 1,426 | $494,000 | 0.12% |
| MOODY ALDRICH PARTNERS LLC | 1,709 | $592,000 | 0.12% |
| RICE HALL JAMES & ASSOCIATES, LLC | 6,836 | $2,370,000 | 0.12% |
| MATRIX PRIVATE CAPITAL GROUP LLC | 578 | $200,000 | 0.11% |
| Caprock Group, LLC | 3,356 | $1,163,000 | 0.11% |
| BRIDGER MANAGEMENT, LLC | 1,444 | $501,000 | 0.11% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.